MERCURY BIOPHARMACEUTICAL CORPORATIMERCURY BIOPHARMACEUTICAL CORPORATIMERCURY BIOPHARMACEUTICAL CORPORATI

MERCURY BIOPHARMACEUTICAL CORPORATI

No trades
See on Supercharts

6932 fundamentals

MERCURY BIOPHARMACEUTICAL CORPORATI financial statements, including revenue, expenses, profit, and loss

The total revenue of 6932 for the last semiannual is 4.72 M TWD, and it's 356.63% higher compared to the previous semiannual. The net income of H1 24 is -18.30 M TWD.

Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: TWD
TTM
Total revenueYoY growth
Gross profitYoY growth
Pretax incomeYoY growth
Net incomeYoY growth
EBITDAYoY growth
EBITYoY growth